Concentrations of canine prostate specific esterase, CPSE, at baseline are associated with the relative size of the prostate at three-year follow-up

BMC Veterinary Research

S. J. Kumari A. Ubhayasekera¹  Jonas Bergquist¹  Sofia Carlin²  Elin Holmroos²  Bodil S. Holst²  Kerstin Hansson²  Sofia Hanås³  Jesper Rydén⁴  Virginie Fouriez-Lablée⁵  Sofie Ödling⁶  Liss-Marie Langborg⁷ 

[1] Department of Chemistry – Biomedical Center, Analytical Chemistry, Uppsala University, Uppsala, Sweden;Department of Clinical Sciences, Swedish University of Agricultural Sciences, Box 7054, SE-750 07, Uppsala, Sweden;Department of Clinical Sciences, Swedish University of Agricultural Sciences, Box 7054, SE-750 07, Uppsala, Sweden;Evidensia Specialist Animal Hospital Strömsholm, Strömsholm, Sweden;Department of Energy and Technology, Applied Statistics and Mathematics, Swedish University of Agricultural Sciences, Uppsala, Sweden;Diagnostic Imaging Clinic, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden;Evidensia Specialist Animal Hospital Strömsholm, Strömsholm, Sweden;ReDog Veterinary Clinic, Västerås, Sweden;

关键词: Dog;    Steroids;    Corticosteroids;    Prostate hyperplasia;    Biomarker;    Ultrasound;   

DOI  :  10.1186/s12917-021-02874-1

来源: Springer

【 摘 要 】

BackgroundEnlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of 16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3 years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids.ResultsOf the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of ≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up. Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated with the difference in Srel between baseline and follow-up.ConclusionsThe results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog. The association between corticosteroids and prostate growth warrants further investigation.

【 授权许可】

CC BY